Abstract:BackgroundSince China has a unique system of delivering HIV care that includes all patients' records. The factors related to CD4+ T-cell recovery and viral suppression in patients who have low CD4+ T cell counts at the initiation of HAART are understudied in the China despite subsequent virological suppression (viral load < 50 copies/mL) is unknown.MethodsThe authors conducted a retrospective cohort study using data from the national HIV treatment sub-database of Zhejiang province to identify records of HIV+ patients. Patient records were included if they were < 16 years of age, had an initial CD4 count < 100 cells/mu L, were on continuous HAART for at least one year by the end of December 31, 2014; and achieved and maintained continued maximum virological suppression (MVS) (< 50 copies/ml) by 9 months after starting HAART. The primary endpoint for analysis was time to first CD4+ T cell count recovery (>= 200, 350, 500 cells/mu L). Cox proportional hazard regression was used to identify the risk factors for CD4+ T cell count recovery to key thresholds (200350, 350-500, >= 00 cells/mu L) by the time of last clinical follow-up (whichever occurred first), key thresholds (follow-up date for analysis), with patients still unable to reach the end-points being censored by the end December 31, 2014 (follow-up date for analysis).ResultsOf the 918 patients who were included in the study, and the median CD4+ T cell count was 39 cells/mu L at the baseline. At the end of follow-up, 727 (79.2%), 363 (39.5%) and 149 (16.2%) patients had return to >= 200, 350, and 500 cells/mu L, respectively. Kaplan-Meier analysis demonstrated that the rate of patients with CD4+ count recovery to >= 200, 350, and 500 cells/mu L after 1 year on HAART was 43.6, 8.6, and 2.5%, respectively, after 3 years on treatment was 90.8, 46.3, and 17.9%, respectively, and after 5 years on HAART was 97.1, 72.2, and 36.4%, respectively. The median time to return to 200-350, 350-500, >= 500cells/mu L was 1.11, 3.33 and 6.91 years, respectively. Factors of age (aHR = 0.77, 95% CI 0.61-0.97), baseline CD4+ count (aHR = 1.60, 95% CI 1.37-1.86), initial regimens, changes in regimen (aHR = 0.58, 95% CI 0.49-0.69), and inclusion of a cotrimoxazole prophylaxis (aHR = 0.66, 95% CI 0.51-0.85) were associated with CD4+ T cell count recovery.ConclusionThe proportion of patients with initially low CD4 counts after nine months of treatment and that achieved continuous virological suppression was greater than 70% for persons with CD4+ count >= 350. Conversely, only 35% of patients recovered to levels of 500 cells/mu L after 5 years of treatment, and levels continued to rise significantly with further long-term HAART. Early HAART intervention will be necessary for achieving effective CD4+ T cell responses and optimal immunological function in HIV+ patients.

Diagnostic accuracy of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy

Accuracy of WHO CD4 cell count criteria for virological failure of antiretroviral therapy

The Impact of Highly Active Antiretroviral Treatment on the Blood Profiles of Patients with Acquired Immune Deficiency Syndrome

The Factors Related To Cd4+T-Cell Recovery And Viral Suppression In Patients Who Have Low Cd4+T Cell Counts At The Initiation Of Haart: A Retrospective Study Of The National Hiv Treatment Sub-Database Of Zhejiang Province, China, 2014

Anti-retroviral therapy for HIV: who should we test and who should we treat?

Risk Factors and Clinical Prediction Models for Low-Level Viremia in People Living with HIV Receiving Antiretroviral Therapy: an 11-Year Retrospective Study

Changes in levels of T cell subpopulations to monitor the response to antiretroviral therapy among HIV-1-infected patients during two years of HIV-1 replication suppression

Study on the application of CD4+ T lymphocyte rapid detection method in treating AIDS

Long-term immune and virological response in HIV-infected patients receiving antiretroviral therapy

Determinants of CD4+ T Cell Recovery During Suppressive Antiretroviral Therapy: Association of Immune Activation, T Cell Maturation Markers, and Cellular HIV-1 DNA.

Predictors of change in CD4 cell count over time for HIV/AIDS patients on ART follow-up in northern Ethiopia: a retrospective longitudinal study

Impact of increasing CD4 count threshold eligibility for antiretroviral therapy initiation on advanced HIV disease and tuberculosis prevalence and incidence in South Africa: an interrupted time series analysis

CD4 cell count and initiation of antiretroviral therapy: trends in seven UK centres, 1997-2003

A prospective evaluation of the diagnostic accuracy of the point-of-care VISITECT CD4 Advanced Disease test in seven countries

Depression: an individual-level early warning indicator of virologic failure in HIV patients in South Africa

Impact of low-level viremia with drug resistance on CD4 cell counts among people living with HIV on antiretroviral treatment in China

Global trends in CD4 count measurement and distribution at first antiretroviral treatment initiation

Prediction-based classification for longitudinal biomarkers

Immuno-Diagnostic Interest in Monitoring CD16+CD56+ (Natural Killer) Cells and CD19+CD45+ (B Lymphocytes) in Individuals Newly Diagnosed with HIV in a Tertiary Care Center

Association of CD4 + Cell Count and HIV Viral Load with Risk of Non-Aids-defining Cancers.

Cell-Associated HIV-1 Unspliced-to-Multiply-Spliced RNA Ratio at 12 Weeks of ART Predicts Immune Reconstitution on Therapy